On May 16, 2018 Celldex Therapeutics, Inc. (NASDAQ:CLDX) reported that two abstracts will be presented at the 2018 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting being held June 1-5, 2018 in Chicago (Press release, Celldex Therapeutics, MAY 16, 2018, View Source [SID1234526701]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The schedule for the presentations is as follows:

Abstract TPS6091: "A phase 2, multicenter, open-label study to evaluate the efficacy and safety of CDX-3379 in combination with cetuximab in patients with advanced head and neck squamous cell carcinoma (HNSCC)" (Bauman, et al)

Poster Session: Head and Neck Cancer
Date and Time: Saturday, June 2, 2018, 1:15 – 4:15 p.m. CDT
Location: Hall A
Abstract 3001: "Anti-CD27 agonist antibody varlilumab with nivolumab for colorectal and ovarian cancer: Phase 1/2 clinical trial results" (Sanborn, et al)

Oral Abstract Session: Developmental Therapeutics—Immunotherapy
Date and Time: Saturday, June 2, 2018, 3:12 – 3:24 p.m. CDT
Location: Hall B1